THE EFFECT OF CURCUMIN SUPPLEMENTATION ON LIPID PROFILES IN HEMODIALYSIS PATIENTS
DOI:
https://doi.org/10.32461/2226-3209.1.2018.178580Abstract
Abstract. The aim of this study was to determine the effect of curcumin on systemic inflammation and
serum lipid profiles in hemodialysis patients. The aim of this study was to determine the effect of curcumin on systemic inflammation and serum lipid profiles in hemodialysis patients. Then, an experimental group received 80 mg of curcumin for 2 months and the control group received placebo. Before and after intervention, after 12 hours of fasting blood cc5, blood samples were taken from patients for triglyceride, cholesterol, HDL-C and LDL-C parameters. Data were then entered into SPSS 16 software and analyzed by Kolmogorov-Smirnov, Chi-square, Fisher test and T-test. According to the results of the analyzes, the results of the assumptions under study indicated that the supplementation of curcumin reduced serum LDL-C concentrations (P <0.05) and increased serum HDL-C (P = 0.003) in hemodialysis patients. Serum cholesterol and serum triglyceride in patients without hemodialysis are equal to (P> 0.05). The results of this study showed that curcumin supplement can be effective in preventing heart disease and can be used as a complementary therapy.
Keywords: Curcumin, Systemic inflammation, Hemodialysis, Serum lipid profile.
References
Fauci AS. Harrison's principles of internal medicine: McGraw-Hill, Medical Publishing Division New
York; 2008.
Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential
mechanisms. Journal of the American Society of Nephrology. 2006;17(8):2106-11.
Stewart GA, Gansevoort R, Mark PB, Rooney E, Mcdonagh TA, Dargie HJ, et al. Electrocardiographic
abnormalities and uremic cardiomyopathy. Kidney international. 2005;67(1):217-26.
Clarke JL, Anderson JL, Carlquist JF, Roberts RF, Horne BD, Bair TL, et al. Comparison of differing C-
reactive protein assay methods and their impact on cardiovascular risk assessment. The American journal of
cardiology. 2005;95(1):155-8.
Goldsmith DJ, Covic A. Coronary artery disease in uremia: Etiology, diagnosis, and therapy. Kidney
international. 2001;60(6):2059-78.
Marcus J, Sarnak MJ, Menon V, Verma S. Homocysteine lowering and cardiovascular disease risk: lost in
translation. Canadian Journal of Cardiology. 2007;23(9):707-10.
Saunders W. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and
chronic kidney disease. 2007.
Shurraw S, Tonelli M. Statins for treatment of dyslipidemia in chronic kidney disease. Peritoneal dialysis
international. 2006;26(5):523-39.
Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end‐stage
renal disease: an emerging threat to patient outcome. Nephrology Dialysis Transplantation. 2003;18(7):1272-80.
SEYFI S, MOKHTARI A. Serum IL-6 level and associated factors: hemodialysis patients. 2008.
Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density
lipoprotein cholesterol levels in the prediction of first cardiovascular events. New England journal of medicine.
;347(20):1557-65.
Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation
practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of internal
medicine. 2003;139(2):137-47.
Wanner C, Metzger T. C‐reactive protein a marker for all cause and cardiovascular mortality in
haemodialysis patients. Nephrology Dialysis Transplantation. 2002;17(suppl_8):29-32.
Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD. Appetite and inflammation,
nutrition, anemia, and clinical outcome in hemodialysis patients. The American journal of clinical nutrition.
;80(2):299-307.
Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis. Arteriosclerosis,
thrombosis, and vascular biology. 1999;19(10):2348-54.
Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human
peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82(2):513-20.
Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human
endothelial cells. Circulation. 20.8-2165:)18(102;00
Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, et al. C-reactive protein in
the arterial intima. Arteriosclerosis, thrombosis, and vascular biology. 2000;20(9):2094-9.
Albert MA, Glynn RJ, Ridker PM. Effect of physical activity on serum C-reactive protein. The American
journal of cardiology. 2004;93(2):221-5.
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of
inflammation and cardiovascular disease. Circulation. 2 :511-499:(3)107;003.
Takemura M, Matsumoto H, Niimi A, Ueda T, Matsuoka H, Yamaguchi M, et al. High sensitivity C-
reactive protein in asthma. European Respiratory Journal. 2006;27(5):908-12.
Iseki K, Tozawa M, Yoshi S, Fukiyama K. Serum C-reactive protein (CRP) and risk of death in chronic
dialysis patients. Nephrology Dialysis Transplantation. 1999;14(8):1956-60.
Archibald G, Bartlett W, Brown A, Christie B, Elliott A, Griffith K, et al. UK Consensus Conference on
early chronic kidney disease—6 and 7 February 200 .7Nephrology Dialysis Transplantation. 2007;22(9):2455-7.
Owen WF. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney
international. 1998;54(2):627-36.
Selim G, Stojceva-Taneva O, Zafirovska K, Sikole A, Gelev S, Dzekova P, et al. Inflammation predicts
all-cause and cardiovascular mortality in haemodialysis patients. Prilozi/Makedonska akademija na naukite i
umetnostite, Oddelenie za bioloski i medicinski nauki= Contributions/Macedonian Academy of Sciences and
Arts, Section of Biological and Medical Sciences. 2006;27(1):133-44.
Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and
cardiovascular mortality in hemodialysis patients. American Journal of Kidney Diseases. 2000;35(3):469-76.
Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk
and mortality in hemodialysis patients. Kidney international. 1999;55(2):648-5.8
Shahbazian H, Atrian A, Yazdanpanah L, Lashkarara GR, Mohtashami AZ. Anti-inflammatory effect of
simvastatin in hemodialysis patients. Jundishapur journal of natural pharmaceutical products. 2015;10(1).
Donmez L, Gokkoca Z, Dedeoglu N. Disability and its effects on quality of life among older people
living in Antalya city center, Turkey. Archives of gerontology and geriatrics. 2005;40(2):213-23.
Nyman A, Josephsson S, Isaksson G. Being part of an enacted togetherness: Narratives of elderly people
with depression. Journal of aging studies. 2012;26(4):410-8.
Shing CM, Adams MJ, Fassett RG, Coombes JS. Nutritional compounds influence tissue factor
expression and inflammation of chronic kidney disease patients in vitro. Nutrition. 2011;27(9.72-967:)
Jayaprakasha GK, Jagan Mohan Rao L, Sakariah KK. Improved HPLC method for the determination of
curcumin, demethoxycurcumin, and bisdemethoxycurcumin. Journal of Agricultural and Food Chemistry.
;50(13):3668-72.
Ataie A, Sabetkasaei M ,Haghparast A, Moghaddam AH, Ataee R, Moghaddam SN. Curcumin exerts
neuroprotective effects against homocysteine intracerebroventricular injection-induced cognitive impairment
and oxidative stress in rat brain. Journal of medicinal food. 2010;13(4):821-6.
Abdollahzad H, Eghtesadi S, Nourmohammadi I, Khadem-Ansari M, Nejad-Gashti H, Esmaillzadeh A.
Effect of vitamin C supplementation on oxidative stress and lipid profiles in hemodialysis patients .International
journal for vitamin and nutrition research. 2009;79(56):281-7.
Dairam A, Fogel R, Daya S, Limson JL. Antioxidant and iron-binding properties of curcumin,
capsaicin, and S-allylcysteine reduce oxidative stress in rat brain homogenate. Journal of Agricultural and Food
Chemistry. 2008;56(9):3350-6.
Yao Q, Lindholm B, Stenvinkel P. Inflammation as a cause of malnutrition, atherosclerotic
cardiovascular disease, and poor outcome in hemodialysis patients. Hemodialysis International. 2004;8(2):118-
Shehzad A, Rehman G, Lee YS. Curcumin in inflammatory diseases. Biofactors. 2013;39(1):69-77.
Shukla PK, Khanna VK, Ali MM, Khan MY, Srimal RC. Anti-ischemic effect of curcumin in rat brain.
Neurochemical research. 2008;33(6):1036-43.
Moreillon JJ, Bowden RG, Deike E, Griggs J, Wilson R, Shelmadine B, et al. The use of an anti-
inflammatory supplement in patients with chronic kidney disease. Journal of Complementary and Integrative
Medicine. 2013;10(1):143-52.
Moreillon JJ, Bowden RG, Deike E, Griggs J, Wilson R, Shelmadine B, et al. The use of an anti-
inflammatory supplement in patients with chronic kidney disease. Journal of Complementary and Integrative
Medicine. 2013;10(1):143-52.
Buyuklu M, Kandemir FM, Ozkaraca M, Set T, Bakirci EM, Topal E. Protective effect of curcumin
against contrast induced nephropathy in rat kidney: what is happening to oxidative stress, inflammation,
autophagy and apoptosis. Eur Rev Med Pharmacol Sci. 2014;18(4):461-70.
Downloads
Issue
Section
License
Authors who publish with this journal agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
